Brian Goodman, Patrick Baeuerle and Todd Foley weren’t exactly looking to start a radiopharmaceuticals company. Rather, the team at MPM Capital — which had been known for its willingness to seed and incubate new ideas for battling cancer — was searching for technologies that could confer “CAR-T like efficacy” in solid tumors. They went through … Continue reading Are radiopharmaceuticals ready for the mainstream? Novartis, Bristol Myers Squibb bet yes on MPM’s platform take